Overall, these findings demonstrate that the CXCR4 antagonist exerts both effects on BCR signaling and nuclear export, restores the function of FOXO3a (Figure 6) and PTEN, reduces the nuclear export of hnRNPA2, and overcomes acquired resistance to BTK inhibitor in DLBCL patients. This evidence concerns the gene PTEN and diffuse large B-cell lymphoma.